Figure 3

Inhibition of exosome secretion from MM cancer cells reduces proliferation and cellular abundance of oncogenic proteins targeted by miR-16. (A) MTS proliferation assay on Hmeso cells after cisplatin treatment, exosome inhibition, or combination of both treatments after 72 hr, n = 6. (B) and (C) MTS proliferation assay on H2595 and H2373 cells, respectively, after cisplatin treatment, exosome inhibition, or combination of both treatments after 72 hr, n = 6 (D) Immunoblot of Hmeso cellular proteins and miR-16 targets CCND1 and BCL2, normalized to β-actin. n = 2. (E) Immunoblot of H2595 cellular protein and miR-16 target CCND1, normalized to β-actin content. n = 2. qPCR of miR-16-5p oncogenes (F) CCND1 and (G) BCL2 after exosome inhibition, as normalized to HPRT endogenous control. *p ≤ 0.05 as compared to control, ^†p ≤ 0.05 as compared to cisplatin treated group by 1-way ANOVA.